BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• 

  The 10 Most Compelling Research Stories of 2021

  Here’s a look at 10 of the more compelling research stories of the year.

  December 20, 2021

   · 

  8 min read

   · 

  Mark Terry
• 

  Drug Development

  Pfizer and BioNTech Hope 3rd Dose is the Charm for Youngest Kids

  After their latest trial delivered disappointing results, Pfizer and BioNTech are ready to test if a third dose of their COVID-19 vaccine would trigger an immune response in very young children.

  December 20, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  FDA

  Argenx’s Regulatory Milestone Offers New Hope for gMG Patients

  VYVGART is the first-and-only neonatal Fc receptor (FcRn) blocker to be approved by the FDA.

  December 20, 2021

   · 

  3 min read

   · 

  Sreetama Dutt
• 

  Policy

  COVID News: Moderna Booster Effective Against Omicron and CDC’s “Test to Stay” Policy

  As the spread of the Omicron variant of COVID-19 picks up speed, vaccine makers are rushing to test their shots against the new mutation, with mixed results.

  December 20, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Policy

  Moderna Seeks Amicable Resolution with NIH over Patent Battle

  Moderna has decided to drop the patent application to “allow more time for discussions with the NIH”, which will be aimed at an amicable resolution.

  December 20, 2021

   · 

  2 min read

   · 

  Alvin Clavines
• 

  Business

  Novartis Deepens BeiGene Oncology Pact, Posts Disappointing Results in CSU

  Novartis announced it has licensed BeiGene’s ociperlimab, a late-stage TIGIT inhibitor, to bolster its immunotherapy pipeline.

  December 20, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Genetown

  Biogen Cuts Price of Much-Debated Alzheimer’s Drug Aducanumab in Half

  Biogen announced that effective January 1, 2022, it will cut the wholesale acquisition cost of its Alzheimer’s drug Aducanumab in half from $56,000 to $28,200 per patient per year.

  December 20, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  FDA

  There’s a New Humira Challenger as Coherus Biosimilar Wins Approval

  Shares of Coherus BioSciences are climbing in premarket trading after the company announced the FDA greenlit the company’s Humira biosimilar Yusimry.

  December 20, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Additional Research Points to Intranasal Defenses Against COVID-19

  Nasal spray vaccine delivery for COVID-19 has been explored by multiple companies since the beginning of the pandemic.

  December 20, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Approves New Drug to Stop Inflammation in Asthma at the Source

  The decision comes after the FDA granted the drug, Tezspire (tezepelumab), Priority Review status on positive results from the PATHFINDER clinical trial program.

  December 20, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN